CDKIs p18INK4cand p57Kip2are involved in quiescence of CML leukemic stem cells after treatment with TKI-Reference-Cited by-同舟云学术

CDKIs p18INK4cand p57Kip2are involved in quiescence of CML leukemic stem cells after treatment with TKI

Published:2016-03-17 Issue:9 Volume:15 Page:1276-1287
ISSN:1538-4101
Container-title:Cell Cycle
language:en
Short-container-title:Cell Cycle

Author:

Moreno-Lorenzana Dafne,Avilés-Vazquez Sócrates,Sandoval Esquivel Miguel Angel,Alvarado-Moreno Antonio,Ortiz-Navarrete Vianney,Torres-Martínez Héctor,Ayala-Sánchez Manuel,Mayani Héctor,Chavez-Gonzalez Antonieta

Publisher

Informa UK Limited

Subject

Cell Biology,Developmental Biology,Molecular Biology

Link

https://tandfonline.com/doi/pdf/10.1080/15384101.2016.1160976

Reference39 articles.

1. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

2. Bcr-Abl Exerts Its Antiapoptotic Effect Against Diverse Apoptotic Stimuli Through Blockage of Mitochondrial Release of Cytochrome C and Activation of Caspase-3

3. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

4. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

5. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SKF-96365 Expels Tyrosine Kinase Inhibitor-Treated CML Stem and Progenitor Cells from the HS27A Stromal Cell Niche in a RhoA-Dependent Mechanism;Cancers;2024-08-08

2. CDK8/19 Inhibition Attenuates G1 Arrest Induced by BCR-ABL Antagonists and Accelerates Death of Chronic Myelogenous Leukemia Cells;2023-09-25

3. Telomere loss is accompanied by decreased pool of shelterin proteins TRF2 and RAP1, elevated levels of TERRA and enhanced glycolysis in imatinib-resistant CML cells;Toxicology in Vitro;2023-08

4. Targeting Cancer Stem Cells as the Key Driver of Carcinogenesis and Therapeutic Resistance;International Journal of Molecular Sciences;2023-01-16

5. Cancer Stem Cells: Biology and Therapeutic Implications;Archives of Medical Research;2022-12